NeoTX poster from the American Association for Cancer Research (AACR) Annual Meeting is now available

The poster from NeoTX Therapeutics’ presentation of interim results from the phase Ib trial with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced or metastatic solid tumors at the American Association for Cancer Research (AACR) annual meeting 14 – 19 April, in Orlando, Florida is now available on the NeoTX website.